Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cartesian Therapeutics (RNAC), Rani Therapeutics Holdings (RANI) and Haemonetics (HAE)

Tipranks - Tipranks - Sat Jan 10, 1:52PM CST

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cartesian Therapeutics (RNAC – Research Report), Rani Therapeutics Holdings (RANI – Research Report) and Haemonetics (HAE – Research Report).

Claim 70% Off TipRanks Premium

Cartesian Therapeutics (RNAC)

Mizuho Securities analyst Uy Ear reiterated a Buy rating on Cartesian Therapeutics today and set a price target of $40.00. The company’s shares closed last Friday at $7.84.

According to TipRanks.com, Ear is a 3-star analyst with an average return of 1.5% and a 41.2% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, ACADIA Pharmaceuticals, and MBX Biosciences, Inc. ;'>

Currently, the analyst consensus on Cartesian Therapeutics is a Strong Buy with an average price target of $35.00, implying a 333.7% upside from current levels. In a report released today, Needham also maintained a Buy rating on the stock with a $42.00 price target.

See the top stocks recommended by analysts >>

Rani Therapeutics Holdings (RANI)

In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Rani Therapeutics Holdings, with a price target of $10.00. The company’s shares closed last Friday at $1.38, close to its 52-week low of $1.24.

According to TipRanks.com, Okunewitch is a 1-star analyst with an average return of -0.7% and a 38.7% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as Radiopharm Theranostics Limited Sponsored ADR, Acrivon Therapeutics, Inc., and BioRestorative Therapies. ;'>

Currently, the analyst consensus on Rani Therapeutics Holdings is a Strong Buy with an average price target of $10.00, a 609.2% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $11.00 price target.

Haemonetics (HAE)

In a report released today, Michael Matson from Needham maintained a Hold rating on Haemonetics. The company’s shares closed last Friday at $82.77.

According to TipRanks.com, Matson is a 3-star analyst with an average return of 1.9% and a 46.0% success rate. Matson covers the Healthcare sector, focusing on stocks such as Insight Molecular Diagnostics, Establishment Labs Holdings, and Zimmer Biomet Holdings. ;'>

Currently, the analyst consensus on Haemonetics is a Moderate Buy with an average price target of $88.43.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).